公开(公告)号：US10705094B2

公开(公告)日：2020-07-07

申请号：US15736520

申请日：2015-10-22

Applicant: UCB Biopharma SRL

Inventor： James Philip O'Connell ,  John Robert Porter ,  Alastair Lawson ,  Boris Kroeplien ,  Stephen Edward Rapecki ,  Timothy John Norman ,  Graham John Warrellow

IPC: G01N33/68 ,  C07K14/525 ,  C07K14/705 ,  C07K16/24 ,  A61K47/64 ,  A61P37/00 ,  C07D401/14 ,  C07D471/00 ,  C07D213/72 ,  C07D235/04 ,  C07D239/26 ,  C07D471/04 ,  A61P35/00

Abstract: It has been demonstrated that certain compounds bind to TNF and stabilise a conformation of trimeric TNF that binds to the TNF receptor. Accordingly, these compounds can be used as modulators of TNF. A new assay for identifying compounds with this mechanism of action is also disclosed.

公开(公告)号：US11472879B2

公开(公告)日：2022-10-18

申请号：US16778523

申请日：2020-01-31

Applicant: UCB Biopharma SRL

Inventor： Helene Margaret Finney ,  Stephen Edward Rapecki ,  Kerry Louise Tyson ,  Michael John Wright

IPC: C07K16/28 ,  A01K67/027 ,  A61K39/00

Abstract: The present disclosure relates to antibody molecules comprising a binding domain specific to CD22, said binding domain comprising SEQ ID NO: 1, 2, 3, 4, 5 and 6 or 7. The disclosure also extends to pharmaceutical compositions comprising said antibody molecules and use of the antibody molecules/compositions in treatment.

公开(公告)号：US11674967B2

公开(公告)日：2023-06-13

申请号：US17013326

申请日：2020-09-04

Applicant: UCB BIOPHARMA SRL

Inventor： James Philip O'Connell ,  John Robert Porter ,  Alastair Lawson ,  Boris Kroeplien ,  Stephen Edward Rapecki ,  Timothy John Norman ,  Graham John Warrellow ,  Tracy Lynn Arakaki ,  Alex Buntin Burgin ,  William Ross Pitt ,  Mark Daniel Calmiano ,  David Andreas Schubert ,  Daniel John Lightwood ,  Rebecca Jayne Munro

IPC: G01N33/68 ,  C07D401/14 ,  C07K14/525 ,  C07D471/00 ,  C07K14/705 ,  C07K16/24 ,  C07D213/72 ,  C07D235/04 ,  C07D239/26 ,  C07D471/04 ,  A61K47/64 ,  A61P37/00 ,  A61P35/00

CPC classification number: G01N33/6845 ,  A61K47/6425 ,  A61P35/00 ,  A61P37/00 ,  C07D213/72 ,  C07D235/04 ,  C07D239/26 ,  C07D401/14 ,  C07D471/00 ,  C07D471/04 ,  C07K14/525 ,  C07K14/70575 ,  C07K16/241 ,  G01N33/6854 ,  G01N33/6863 ,  C07K2317/55 ,  C07K2317/92 ,  G01N2333/525 ,  G01N2500/02

Abstract: A new, stable trimeric TNFα structure is disclosed with distorted symmetry which can bind to the TNFR1 receptor to attenuate signalling therefrom, which can be used in the treatment and/or prevention of diseases associated with the soluble TNFα/TNFR1 interaction. Membrane-bound TNFα is not affected in its ability to signal through TNFR2, and thus the new structure of TNFα may be used in therapies which do not significantly raise the risk of infection or malignancy.

公开(公告)号：US11448655B2

公开(公告)日：2022-09-20

申请号：US16883859

申请日：2020-05-26

Applicant: UCB BIOPHARMA SRL

Inventor： James Philip O'Connell ,  John Robert Porter ,  Alastair Lawson ,  Boris Kroeplien ,  Stephen Edward Rapecki ,  Timothy John Norman ,  Graham John Warrellow

IPC: G01N33/68 ,  C07K14/525 ,  C07K16/24 ,  A61K47/64 ,  A61P37/00 ,  A61P35/00 ,  C07D401/14 ,  C07D471/00 ,  C07K14/705 ,  C07D213/72 ,  C07D235/04 ,  C07D239/26 ,  C07D471/04

Abstract: It has been demonstrated that certain compounds bind to TNF and stabilise a conformation of trimeric TNF that binds to the TNF receptor. Accordingly, these compounds can be used as modulators of TNF. A new assay for identifying compounds with this mechanism of action is also disclosed.

公开(公告)号：US11261252B2

公开(公告)日：2022-03-01

申请号：US16513002

申请日：2019-07-16

Applicant: UCB BIOPHARMA SRL

Inventor： Helene Margaret Finney ,  Stephen Edward Rapecki ,  Michael John Wright ,  Kerry Louise Tyson

IPC: C07K16/28 ,  C07K16/18 ,  A61K39/00

Abstract: The present disclosure relates to multispecific molecule comprising a binding domain specific to the antigen CD22 and a binding domain specific to the antigen CD79a and/or CD79b, compositions comprising the same and use of both in treatment, for example the treatment of autoimmune disease.

公开(公告)号：US10883996B2

公开(公告)日：2021-01-05

申请号：US15736336

申请日：2015-10-22

Applicant: UCB BIOPHARMA SRL

Inventor： James Philip O'Connell ,  John Robert Porter ,  Alastair Lawson ,  Boris Kroeplien ,  Stephen Edward Rapecki ,  Timothy John Norman ,  David James McMillan ,  Graham John Warrellow ,  Daniel Christopher Brookings ,  Rikki Peter Alexander

IPC: G01N33/68 ,  C07K14/525 ,  C07K14/705 ,  C07K16/24 ,  C07D401/14 ,  C07D471/00 ,  C07D213/72 ,  C07D235/04 ,  C07D239/26 ,  C07D471/04 ,  A61K47/64 ,  A61P37/00 ,  A61P35/00

Abstract: The invention is in the field of TNF signalling. Compounds have been identified which are capable of modulating signalling of TNF trimers through receptors. Methods of identifying such compounds are therefore provided. The compounds themselves have utility in therapy.